The Commission Strategy on TB vaccine research TB research has been supported from the EU Framework programmes for Research & Development (FP) in a sustainable way for more than 10 years. There has been a strategy behind, aiming at achieving substantial impact on development of new tools, such as diagnostics, drugs and vaccines, and on the research capacity in EU Member States and developing countries. Hannu Lång Fighting Infectious Diseases and advancing Public Health Health Directorate Research & Innovation DG European Commission, Brussels, Belgium

Industrial Leadership How? The ecosystem for EU Health Research Resources required PUSH PULL "Valley of Death" Risk level Discovery PoC Preclinic Phase 1/2a Phase 2 Phase 3 Commercial EDCTP FP7/H2020 Grants Horizon Prize SME-Instrument ERC MSCA H2020 pillars InnovFin ID All this contributes to building the EU ecosystem for health research, which covers research from discovery all the way to commercialisation. Different pillars of the H2020 programme aim at supporting the indicated tools that cover the pipeline. Excellent Science IMI Industrial Leadership Societal Challenges

The policy framework of TB vaccine research in FP9 A European One Health Action Plan against Antimicrobial Resistance (AMR) Council Recommendation on strengthened cooperation against vaccine preventable diseases Commission communication on Infectious Diseases Commission staff working document on Combatting HIV/AIDS, Viral Hepatitis, sexually transmitted diseases and Tuberculosis

The EDCTP2 Programme (2014-2024) The EDCTP Programme has been instrumental in building research capacity for poverty-related diseases like TB in Sub-Saharan Africa. Importantly, in the EDCTP2 programme the African Member States participate as co-owners of the programme, and this helps the development and implementation of national TB research plans. Synergy Capacity for Clinical Trials in Africa Clinical Trials in Africa on PRNDs www. edctp.org